ProstACT Global Phase 3 Study (Part 1) Achieves Primary Objectives

2026-03-09 - 23:08

Webcast and conference call to be held today, Tuesday March 10 at 9:30 a.m. AEDT (Monday March 9 at 6:30 p.m. EDT). Investors can register at the following link: https://s1.c-conf.com/diamondpass/10053620-ju7y6t.html MELBOURNE, Australia and INDIANAPOLIS, March 10, 2026 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that Part 1 of the ProstACT